Newsfeeds - Spark Newswire

2 minute read

FDA
News

Monopar Initiates Open-Label Phase 1b Clinical Trial Evaluating Camsirubicin In Patients With Advanced Soft Tissue Sarcoma

Today, 3:25 AM

Monopar Therapeutics Inc. (NASDAQ:MNPR), a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients, today

MNPR

1 minute read

FDA
News

Monopar Therapeutics Sponsored Study Titled ‘Camsirubicin + Pegfilgrastim to Determine MTD in ASTS’ Posted To ClinicalTrials.Gov; Study Not Yet Recruiting

By Benzinga Newsdesk

Today, 3:25 AM

https://clinicaltrials.gov/ct2/show/NCT05043649

MNPR

4 minute read

54 Biggest Movers From Yesterday

By Lisa Levin

Today, 3:25 AM

Gainers eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR) shares jumped 111.8% to settle at $27.17 on Wednesday after jumping 50% on Tuesday.

ABSI

2 minute read

Movers

12 Health Care Stocks Moving In Wednesday’s After-Market Session

By Benzinga Insights

Today, 3:25 AM

Gainers

BYSI

1 minute read

Monopar Therapeutics Q2 EPS $(0.17) Down From $(0.14) YoY

By Bill Haddad

Today, 3:25 AM

Monopar Therapeutics (NASDAQ:MNPR) reported quarterly losses of $(0.17) per share. This is a 21.43 percent decrease over losses of $(0.14) per share from the same period last year.

MNPR

2 minute read

FDA
News

Monopar Therapeutics Reports Reached Target Number Of Clinical Sites In Phase 2b Portion Of 2b/3 Validive VOICE Trial

By Benzinga Newsdesk

Today, 3:25 AM

Monopar Therapeutics Inc. (NASDAQ:MNPR), a clinical-stage biopharmaceutical company primarily focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients,

MNPR

1 minute read

12 Health Care Stocks Moving In Friday’s Pre-Market Session

By Benzinga Insights

Today, 3:25 AM

AKU

1 minute read

Monopar, National University of Singapore Team Up For Preclinical Assessment Of MNPR-202 In Cancer Settings

By Vandana Singh

Today, 3:25 AM

Monopar Therapeutics Inc (NASDAQ:MNPR) collaborates with the Cancer Science Institute of Singapore to evaluate the activity of MNPR-202 and related analogs…

MNPR

1 minute read

12 Health Care Stocks Moving In Thursday’s Pre-Market Session

By Benzinga Insights

Today, 3:25 AM

BSGM

2 minute read

Monopar Announces New Drug Candidate, MNPR-202; Says Enters Into Collaboration Agreement With National University Of Singapore For Preclinical Evaluation In Cancer

By Benzinga Newsdesk

Today, 3:25 AM

Monopar Therapeutics Inc. (NASDAQ:MNPR), a clinical-stage biopharmaceutical company primarily focused on developing proprietary therapeutics designed to extend life or improve the quality of

MNPR